Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW. Kwak JY, et al. Among authors: bunworasate u. Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939746 Clinical Trial.
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.
Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R. Kim DW, et al. Among authors: bunworasate u. Leuk Res. 2010 Nov;34(11):1459-71. doi: 10.1016/j.leukres.2010.03.033. Leuk Res. 2010. PMID: 20430443
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
Do YR, Kwak JY, Kim JA, Kim HJ, Chung JS, Shin HJ, Kim SH, Bunworasate U, Choi CW, Zang DY, Oh SJ, Jootar S, Reksodiputro AH, Lee WS, Mun YC, Kong JH, Caguioa PB, Kim H, Park J, Kim DW. Do YR, et al. Among authors: bunworasate u. Br J Haematol. 2020 Apr;189(2):303-312. doi: 10.1111/bjh.16381. Epub 2020 Feb 3. Br J Haematol. 2020. PMID: 32012231 Free PMC article. Clinical Trial.
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
Drach J, Huang H, Samoilova O, Belch A, Farber C, Bosly A, Novak J, Zaucha J, Dascalescu A, Bunworasate U, Masliak Z, Vilchevskaya K, Robak T, Pei L, Rooney B, van de Velde H, Cavalli F. Drach J, et al. Among authors: bunworasate u. Leuk Lymphoma. 2018 Apr;59(4):896-903. doi: 10.1080/10428194.2017.1365855. Epub 2018 Jan 17. Leuk Lymphoma. 2018. PMID: 29338540 Clinical Trial.
Isolated Extramedullary Relapse After Human Leukocyte Antigen-Matched Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Case Reports and Literature Review.
Khemaphiphat P, Wudhikarn K, Bunworasate U, Chanswangphuwana C. Khemaphiphat P, et al. Among authors: bunworasate u. Transplant Proc. 2021 Jul-Aug;53(6):2029-2034. doi: 10.1016/j.transproceed.2021.02.030. Epub 2021 May 5. Transplant Proc. 2021. PMID: 33962773 Review.
Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Polprasert C, Niparuck P, Rattanathammethee T, Chuncharunee S, Kobbuaklee S, Songserm K, Suksusut A, Trithiphen S, Lanamtieng T, Kongkiatkamon S, Chanswangphuwana C, Lawasut P, Bunworasate U, Rojnuckarin P. Polprasert C, et al. Among authors: bunworasate u. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e293-e299. doi: 10.1016/j.clml.2021.10.015. Epub 2021 Nov 2. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34840089
Prevalence and clinical outcomes of germline variants among patients with myeloid neoplasms.
Kongkiatkamon S, Niparuck P, Rattanathammethee T, Kobbuaklee S, Suksusut A, Wudhikarn K, Ittiwut C, Chetruengchai W, Chuncharunee S, Bunworasate U, Suphapeetiporn K, Rojnuckarin P, Polprasert C. Kongkiatkamon S, et al. Among authors: bunworasate u. J Clin Pathol. 2024 May 22:jcp-2023-209264. doi: 10.1136/jcp-2023-209264. Online ahead of print. J Clin Pathol. 2024. PMID: 38777570
Prognostic factors and impact of CMV reactivation on acute myeloid leukemia patients after HLA-matched myeloablative allogeneic stem cell transplantation in a high CMV prevalence country.
Chanswangphuwana C, Wudhikarn K, Watanaboonyongcharoen P, Kansuwan P, Sukperm A, Bunworasate U. Chanswangphuwana C, et al. Among authors: bunworasate u. Hematol Transfus Cell Ther. 2023 Jul;45 Suppl 2(Suppl 2):S51-S56. doi: 10.1016/j.htct.2022.01.006. Epub 2022 Feb 10. Hematol Transfus Cell Ther. 2023. PMID: 35172942 Free PMC article.
Genetic mutations associated with blood count abnormalities in myeloid neoplasms.
Polprasert C, Kongkiatkamon S, Niparuck P, Rattanathammethee T, Wudhikarn K, Chuncharunee S, Kobbuaklee S, Suksusut A, Lanamtieng T, Lawasut P, Asawapanumas T, Bunworasate U, Rojnuckarin P. Polprasert C, et al. Among authors: bunworasate u. Hematology. 2022 Dec;27(1):765-771. doi: 10.1080/16078454.2022.2094134. Hematology. 2022. PMID: 35766510
55 results